文献速递真菌感染细菌感染、耐药与抗菌药物

延长给药间隔脂质体两性霉素B用于儿童新诊断AML抗真菌预防的回顾性多中心研究

Liposomal amphotericin B retrospective multicentre study on mycosis prophylaxis (L-AmB_RUSCO): tolerability and safety of extended-dosing primary antifungal prophylaxis in children with newly diagnosed acute myeloid leukaemia.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

OBJECTIVES: To evaluate the tolerability and safety of extended-dosing liposomal amphotericin B (LAmB) as primary antifungal prophylaxis against invasive fungal disease (IFD) in children receiving chemotherapy for newly diagnosed acute myeloid leukaemia (AML); breakthrough proven…

要点

  • 延长给药间隔LAmB(1 mg/kg每周三次、2.5 mg/kg每周两次或5 mg/kg每周一次)在儿童AML中总体可耐受。
  • 低钾血症(48%)和肝毒性(19%)为主要实验室不良事件,均与剂量相关。
  • 15%疗程因毒性停药,突破性确诊或临床诊断IFD发生率为3%,无对照组需谨慎解读。

核心结论

  • 延长给药间隔LAmB是儿童新诊断AML初级抗真菌预防中耐受性尚可的覆盖霉菌的选项,尤其适用于三唑类禁忌或每日静脉棘白菌素不实用时。
  • 观察到的突破性IFD发生率低,但因缺乏对照组应谨慎解读。

研究设计与样本

  • 评估临床和实验室不良事件以评价耐受性与安全性;突破性确诊或临床诊断IFD按EORTC/MSG标准记录为探索性次要终点。

主要发现

  • 首次LAmB给药中位年龄91个月(IQR 26–156)。
  • 中位治疗持续时间13周(IQR 3–21),每次输注中位剂量2.7 mg/kg,中位估计累积剂量77.6 mg/kg(IQR 21.3–110.1)。
  • 临床不良事件发生于21%的疗程,以皮疹和腰骶部疼痛为主。
  • 实验室不良事件主要为低钾血症(48%)和肝毒性(19%),两者均呈剂量相关。
  • 15%的疗程因毒性停药;突破性确诊或临床诊断IFD发生于3%的病例。

临床怎么用

  • 对于新诊断AML化疗儿童,当三唑类禁忌或每日静脉棘白菌素不实用时,可考虑延长给药间隔LAmB作为初级抗真菌预防。
  • 治疗期间应监测低钾血症和肝毒性,二者呈剂量相关,15%疗程因毒性停药。
  • 突破性IFD发生率低(3%),但缺乏对照组的观察性设计限制其因果推断。

局限性

  • 回顾性观察性研究,无对照组,突破性IFD低发生率应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the tolerability and safety of extended-dosing liposomal amphotericin B (LAmB) as primary antifungal prophylaxis against invasive fungal disease (IFD) in children receiving chemotherapy for newly diagnosed acute myeloid leukaemia (AML); breakthrough proven or probable IFD was assessed as an exploratory secondary endpoint. METHODS: This retrospective, multinational, multicentre observational study included children treated for newly diagnosed AML between January 2019 and December 2023. LAmB was administered according to local protocols at 1 mg/kg three times weekly, 2.5 mg/kg twice weekly or 5 mg/kg once weekly. Clinical and laboratory adverse events (AEs) were assessed to evaluate tolerability and safety. Breakthrough proven or probable IFD, defined according to EORTC/MSG criteria, was recorded as an exploratory secondary outcome. RESULTS: Eighty-six courses of extended-dosing LAmB were analysed. The median age at first LAmB administration was 91 months (IQR 26-156). The median treatment duration was 13 weeks (IQR 3-21) at a median dose of 2.7 mg/kg per infusion, with a median estimated cumulative dose of 77.6 mg/kg (IQR 21.3-110.1). Clinical AEs occurred in 21% of courses, predominantly skin rash and lumbosacral pain. Laboratory AEs were mainly hypokalaemia (48%) and hepatotoxicity (19%), both dose related. Treatment discontinuation due to toxicity occurred in 15% of courses. Breakthrough proven or probable IFD occurred in 3% of cases. CONCLUSIONS: Extended-dosing LAmB represents a reasonably well-tolerated mould-active option for primary antifungal prophylaxis in children with newly diagnosed AML, particularly when triazoles are contraindicated or daily intravenous echinocandin administration is impractical; the low observed rate of breakthrough IFD should be interpreted cautiously given the absence of a comparator group.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ricci E, Mesini A, Mariani M, et al. Liposomal amphotericin B retrospective multicentre study on mycosis prophylaxis (L-AmB_RUSCO): tolerability and safety of extended-dosing primary antifungal prophylaxis in children with newly diagnosed acute myeloid leukaemia. J Antimicrob Chemother. 2026. PMID: 42606142. doi:10.1093/jac/dkag289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。